Paper · 41125751
Erdafitinib suppresses pathological retinal angiogenesis via dual targeting of FGFR and VEGFR2 signaling.
Mo Y and 7 others. Sci Rep, 2025. Cited by 1 paper, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Erdafitinib suppresses pathological retinal angiogenesis via dual targeting of FGFR and VEGFR2 signaling. Papers, record 41125751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41125751
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Erdafitinib suppresses pathological retinal angiogenesis via dual targeting of FGFR and VEGFR2 signaling.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Signal Transduction | Major topic |
| Vascular Endothelial Growth Factor Receptor-2 | Major topic |
| Quinoxalines | Major topic |
| Pyrazoles | Major topic |
| Retinal Neovascularization | Major topic |
| Receptors, Fibroblast Growth Factor | Major topic |
| Neovascularization, Pathologic | Major topic |
| Animals | |
| Zebrafish | |
| Humans | |
| Human Umbilical Vein Endothelial Cells | |
| Mice | |
| Disease Models, Animal | |
| Molecular Docking Simulation | |
| Cell Movement | |
| Angiogenesis Inhibitors | |
| Angiogenesis |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2020M672502 | China Postdoctoral Fellowship Program | PubMed | ||
| 2022JJ50039 | Natural Science Foundation of Hunan Province | PubMed | ||
| 2021ZYX10 | Hunan Provincial Department of Education, Open Fund for First-Class Disciplines at Hunan University of Chinese Medicine | PubMed | ||
| 2024YR28 | Yiyang Science and Technology Innovation Plan Project | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31,803,255 | Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. | Ther Adv Med Oncol | 2019 | https://conductscience.org/library/papers/31803255 | PubMed |
| 2 | 38,085,518 | Spent hops extract (Humulus Lupulus L.) attenuates inflammation and angiogenesis of the retina via the nuclear factor-kappaB and protein kinase B/extracellular signal-regulated kinase pathways. | J Physiol Pharmacol | 2023 | https://conductscience.org/library/papers/38085518 | PubMed |
| 3 | 24,529,623 | EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma. | Biomaterials | 2014 | https://conductscience.org/library/papers/24529623 | PubMed |
| 4 | 33,655,556 | Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. | Cell Prolif | 2021 | https://conductscience.org/library/papers/33655556 | PubMed |
| 5 | 19,816,419 | Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. | Nat Protoc | 2009 | https://conductscience.org/library/papers/19816419 | PubMed |
| 6 | 31,282,895 | HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis. | J Vis Exp | 2019 | https://conductscience.org/library/papers/31282895 | PubMed |
| 7 | 19,757,106 | Computer-aided quantification of retinal neovascularization. | Angiogenesis | 2009 | https://conductscience.org/library/papers/19757106 | PubMed |
| 8 | 37,380,559 | Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors. | Eur Urol | 2024 | https://conductscience.org/library/papers/37380559 | PubMed |
| 9 | 35,933,500 | Pathologically high intraocular pressure disturbs normal iron homeostasis and leads to retinal ganglion cell ferroptosis in glaucoma. | Cell Death Differ | 2023 | https://conductscience.org/library/papers/35933500 | PubMed |
| 10 | 23,183,629 | Regular care and maintenance of a zebrafish (Danio rerio) laboratory: an introduction. | J Vis Exp | 2012 | https://conductscience.org/library/papers/23183629 | PubMed |
1 to 10 of 50
See all 50 referencesCited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42,430,785 | A graph retrieval-augmented generation pipeline for systematic drug target discovery: validation and application to ocular neovascularization. | Brief Bioinform | 2026 | https://conductscience.org/library/papers/42430785 |
Source PubMed
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41125751
GET https://conductscience.org/api/papers/v1/41125751/references?page=2